Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy

NCT02055144 · clinicaltrials.gov ↗
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy